Viral Hepatitis and Retrovirus Diagnostic Tests

Global Viral Hepatitis and Retrovirus Diagnostic Tests Market to Reach US$7.7 Billion by 2030

The global market for Viral Hepatitis and Retrovirus Diagnostic Tests estimated at US$4.8 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 11.3% CAGR

The Viral Hepatitis and Retrovirus Diagnostic Tests market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Viral Hepatitis and Retrovirus Diagnostic Tests Market - Key Trends & Drivers Summarized

Why Is Early and Accurate Diagnosis Critical for Viral Hepatitis and Retroviral Infections?
The burden of viral hepatitis and retroviral infections continues to rise globally, driving an urgent need for early and precise diagnostic solutions. With hepatitis B and C responsible for millions of chronic infections and a leading cause of liver cancer, governments and healthcare agencies are ramping up screening efforts to control disease progression. Similarly, human immunodeficiency virus (HIV) infections remain a significant global health challenge, necessitating routine and high-sensitivity diagnostic tests. The adoption of polymerase chain reaction (PCR)-based tests and next-generation sequencing (NGS) technologies has revolutionized the accuracy of virus detection, enabling healthcare providers to diagnose infections at an early stage. Additionally, the rise of rapid antigen-based and point-of-care (POC) testing solutions is expanding access to timely diagnosis, particularly in low-resource settings where centralized laboratory infrastructure is limited.

How Is Technology Reshaping Viral Diagnostic Testing?
Technological advancements are playing a pivotal role in transforming viral hepatitis and retrovirus diagnostics. The integration of artificial intelligence (AI) and machine learning into diagnostic platforms is improving test accuracy and predictive analytics, facilitating early intervention and disease management. Automated, multiplexed testing platforms capable of detecting multiple viral strains in a single assay are gaining traction in clinical settings, reducing diagnostic turnaround times and streamlining patient management. Additionally, the development of portable molecular diagnostic devices is addressing the growing need for decentralized testing, enabling real-time viral load monitoring in remote and rural areas. The adoption of microfluidics and lab-on-a-chip technologies is also improving diagnostic efficiency, ensuring minimal sample volume requirements and rapid detection capabilities.

What Market Dynamics Are Driving Adoption of Advanced Diagnostic Solutions?
A surge in government-led screening initiatives and universal healthcare coverage programs is expanding the adoption of viral hepatitis and retrovirus diagnostic tests. Countries with high endemicity, particularly in Asia-Pacific and sub-Saharan Africa, are investing heavily in national screening programs to curb transmission rates and enhance patient outcomes. The increasing emphasis on home-based self-testing solutions is also reshaping the market, particularly in HIV diagnostics, where confidential and convenient testing is gaining acceptance. Furthermore, the growing prevalence of co-infections, such as hepatitis C and HIV, is driving demand for combined diagnostic assays, allowing for comprehensive patient management. The rapid expansion of telemedicine and digital health solutions is further strengthening the diagnostic landscape by integrating remote testing capabilities and digital result reporting.

The growth in the viral hepatitis and retrovirus diagnostic tests market is driven by several factors, including the rising global disease burden, technological advancements in diagnostic methodologies, and increasing government support for large-scale screening programs. The expansion of molecular and point-of-care diagnostics is enabling faster, more accurate, and more accessible testing, particularly in underserved regions. The shift towards AI-driven diagnostics and digital health platforms is further enhancing market dynamics, improving efficiency in disease detection and patient management. Additionally, growing investments in research and development (R&D) are leading to innovations in highly sensitive, multiplexed, and portable testing solutions, catering to evolving healthcare needs. The increasing demand for early-stage diagnostics to prevent long-term complications and improve treatment outcomes is expected to sustain market growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Viral Hepatitis and Retrovirus Diagnostic Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Segment (Viral Hepatitis & Retrovirus Diagnostic Tests)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 31 Featured) -

• Abbott Diagnostics
• Amkay Products
• AOV International
• Apothecaries Sundries Manufacturing
• BD
• Beckman Coulter
• Bhat Bio-tech
• BioMerieux
• Bioneovan
• Bio-Rad
• Cepheid
• Chembio
• DiaSorin
• Enzo Biochem
• Fujirebio
• Gemc Technology
• Grifols
• Hangzhou Deangel Biological Engineering
• Hangzhou Heo Bio-Tech
• Hologic
• Horiba
• Innovation Biotech
• Jaksh Enterprises
• Krishco Medical Products
• Roche Diagnostics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.